IKT · Inhibikase Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.93
Note written ·
Price against the kill line
21.2% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.93, on record since 11 November 2026. The shares are down 36.4% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.93, the 200-day average of closes (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 June 2026, filed 11 August 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Free cash flow, four quarters ($M)
- −49.4
- Free-cash-flow yield (%)
- −23.2
All filed numbers
What Inhibikase Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) |
|---|---|---|
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −69.2 | −20.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +118.7 |
| Operating cash flow ($M) | −49.4 |
| Capital spending ($M) | 0.0 |
| Free cash flow ($M) | −49.4 |
| Cash and short-term investments ($M) | 51.7 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 189 |
| Market value ($M) | 213 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.1 |
| Free-cash-flow yield (%) | −23.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 14.0% of shares outstanding sold short, 31.1 days of average trading to cover, +1.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $3.0M | $0 |
The thesis
Inhibikase Therapeutics is a one-drug company whose third-quarter report on 10 November 2026 showed a larger cash balance and a faster trial rollout, yet the shares closed at $1.55 that day, 38.5% below the $2.52 52-week high (adjusted daily closes). The case now rests on whether the funding runway holds through the 2027 safety readout, and the dilution that came with it is the main weight on the shares.
The drug, IKT-001, is an imatinib prodrug in the Phase 3 IMPROVE-PAH trial for pulmonary arterial hypertension (PAH). The company reported cash, equivalents and marketable securities of $193.3 million on 30 September 2026, up from $159.0 million on 30 June 2026. Its Q3 net loss was $20.5 million, or $0.10 per share, and the stock-data feed showed that figure beating the $0.11 consensus loss estimate.
The story is well known: the story is well known and the shares have fallen 35.7% over three months to the 10 November 2026 close. Chardan Capital's $1.50 target (Neutral, initiated 13 October 2026) sits just under the market price. The decisive clinical data is mid-2028 by management's projection, so the events in between are enrollment, interim safety and cash updates.
Bullish and bearish views on Inhibikase Therapeutics, Inc.
The bull case on Inhibikase Therapeutics, Inc. (IKT), in brief: cash grew through the quarter. The bear case: the price keeps sliding.
Bull case
- Cash grew through the quarter. The 10 November 2026 report put cash and marketable securities at $193.3 million on 30 September 2026, against $159.0 million three months earlier (11 August 2026 report). Management says cash and the July financing support operations through Part B topline results, assuming full and timely exercise of the Series A and B warrants.
- Trial activation is accelerating. The company reported 79 of a planned 180 clinical sites activated and approvals in 28 countries as of November 2026, up from 46 active sites and 26 countries in the 8 September 2026 presentation.
- Regulatory support exists. The FDA granted Orphan Drug Designation to IKT-001 for PAH on 23 July 2026 (company announcement via Benzinga).
- Some analysts remain strongly positive. Google Finance listed H.C. Wainwright reiterating a Buy with an $8.00 target on 31 July 2026. That is the firm's view and predates the latest price decline.
Bear case
- The price keeps sliding. The close fell from $2.00 on 2 October 2026 to $1.62 on 28 October 2026 and $1.55 on 10 November 2026. The 14-day relative strength index was 44.8 on 10 November 2026 after reading 33.5 on 28 October 2026.
- Dilution widened. The Q3 report counts 140.3 million common shares and 60.6 million pre-funded warrants on 30 September 2026, against 132.0 million and 42.5 million on 30 June 2026. The report says 18,030,000 of the 25 million shares sold to RA Capital in July were exchanged for pre-funded warrants.
- Funding depends on warrant exercise. The company's runway guidance through Part B topline assumes full and timely exercise of the Series A and B warrants, which is harder to count on with the shares below the $2.00 July financing price.
- Spending keeps rising. Research and development expense was $15.0 million in Q3 2026 and $39.2 million for nine months; the Q2 figure was $13.4 million against $5.3 million a year earlier.
- The readout is far away. Part A interim safety results (50 patients) are due in the first half of 2027, and Part A efficacy (change in pulmonary vascular resistance at Week 24) is projected for mid-2028.
- A cautious target sits near the price. Chardan Capital's Neutral rating carries a $1.50 target, 3.2% below the 10 November 2026 close.
Price setup
The adjusted close was $1.55 on 10 November 2026, with a 52-week high of $2.52 (−38.5%). The 3-month price change is −35.7%. On 28 September 2026 MarketBeat gave the 50-day moving average as $2.35 and the 200-day as $2.01, both well above the current price.
The first support reference is the $1.50 level, which equals Chardan's target and sits 3.2% under the last close. A close below it would put the shares under the one published Neutral target.
Catalysts ahead
- 16 November 2026: Jefferies fireside chat with management. Management commentary on enrollment, spending and warrant exercise may update the funding picture.
- 1 December 2026: One-on-one investor meetings with Evercore. Another venue for funding and trial-timing commentary; no data release is scheduled.
- 2027 H1 (company projection): IMPROVE-PAH Part A interim safety readout (n=50). The first trial data in the program.
What would change the view
A daily close above $1.93, the 200-day average of closes (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
The shares trade on company-specific financing and trial news. No sector theme drives them today. Other single-asset, pre-revenue biotechs with open at-the-market facilities show the same sensitivity to financing prices, but the 10 November 2026 report and the Part A readouts are the events that move this stock.
The evidence, claim by claim (7)
- Cash, equivalents and marketable securities $193.3M at 30 September 2026, versus $159.0M at 30 June 2026; Q3 net loss $20.5M ($0.10 per share); R&D $15.0M; SG&A $7.2M. Q3 2026 results release, Form 8-K Exhibit 99.1 · as of
- 140.3M common shares and 60.6M pre-funded warrants outstanding at 30 September 2026; 18,030,000 of the 25M July ATM shares were exchanged for pre-funded warrants. Q3 2026 results release, Form 8-K Exhibit 99.1 · as of
- 79 of a planned 180 clinical sites activated and regulatory approvals in 28 countries; Part A interim safety readout (n=50) planned first half 2027. Q3 2026 results release, Form 8-K Exhibit 99.1 · as of
- Runway guidance: cash and the July financing fund operations through Part B topline, assuming full and timely exercise of Series A and B warrants. Q3 2026 results release, Form 8-K Exhibit 99.1 · as of
- Adjusted close $1.55, 38.5% below the $2.52 52-week high; three-month price change −35.7%; RSI(14) 44.8. Split/dividend-adjusted daily closes · as of
- Chardan Capital initiated coverage with a Neutral rating and a $1.50 price target. Analyst-rating news report, 13 October 2026 · as of
- Q3 EPS of $(0.10) versus a $(0.11) consensus estimate. Stock-data news feed · as of
Sources
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…